Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
05 Janeiro 2024 - 6:05PM
Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN)
today announced that it will report its fourth quarter and full
year 2023 financial and operating results on Friday, February 2,
2024, before the U.S. financial markets open. The Company will host
a conference call and simultaneous webcast at 8:30 AM Eastern Time
that day.
Conference Call Information
Participants may access the conference call live via webcast on the
‘Investors and Media’ page of Regeneron’s website at
https://investor.regeneron.com. To participate via telephone,
please register in advance at this link. Upon registration, all
telephone participants will receive a confirmation email detailing
how to join the conference call, including the dial-in number along
with a unique passcode and registrant ID that can be used to access
the call. A replay and transcript of the conference call and
webcast will be archived on the Company’s website for at least 30
days.
About Regeneron Regeneron is a
leading biotechnology company that invents, develops, and
commercializes life-transforming medicines for people with serious
diseases. Founded and led for over 35 years by
physician-scientists, Regeneron's unique ability to repeatedly and
consistently translate science into medicine has led to numerous
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in Regeneron's laboratories.
Regeneron's medicines and pipeline are designed to help patients
with eye diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, hematologic conditions,
infectious diseases, and rare diseases.
Regeneron is accelerating and improving the
traditional drug development process through its
proprietary VelociSuite® technologies, such
as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully
human antibodies and bispecific antibodies, and through
ambitious research initiatives such as the Regeneron Genetics
Center®, which is conducting one of the largest genetics sequencing
efforts in the world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron on
LinkedIn.
Contact Information: Investor
Relations Ryan Crowe 914.847.8790 ryan.crowe@regeneron.com
Corporate Communications Christina Chan
914.847.8827 christina.chan@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024